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ABSTRACT 
Background 
Granulocyte-colony stimulating factor (G-CSF) shows promise as a treatment for 
stroke. This systematic review assesses G-CSF in experimental ischaemic stroke. 
 
Methods 
Relevant studies were identified with searches of Medline, Embase and PubMed. 
Data were extracted on stroke lesion size, neurological outcome and quality, and 
analysed using Cochrane Review Manager using random effects models; results are 
expressed as standardised mean difference (SMD) and odds ratio (OR). 
 
Results 
Data were included from 19 publications incorporating 666 animals. G-CSF reduced 
lesion size significantly in transient (SMD -1.63, p<0.00001) but not permanent 
(SMD -1.56, p=0.11) focal models of ischaemia. Lesion size was reduced at all 
doses and with treatment commenced within 4 hours of transient ischaemia. 
Neurological deficit (SMD -1.37, p=0.0004) and limb placement (SMD -1.88, 
p=0.003) improved with G-CSF; however, locomotor activity (>4 weeks post 
ischaemia) was not (SMD 0.76, p=0.35). Death (OR 0.27, p<0.0001) was reduced 
with G-CSF. Median study quality was 4 (range 0-7/8); Egger’s test suggested 
significant publication bias (p=0.001). 
 
Conclusions 
G-CSF significantly reduced lesion size in transient but not permanent models of 
ischaemic stroke. Motor impairment and death were also reduced. Further studies 
assessing dose-response, administration time, length of ischaemia and long-term 
functional recovery are needed. 
INTRODUCTION 
 
Stroke has enormous consequences both for the individual and society. Finding an 
effective treatment for this burden is proving challenging and protection of the 
neurovascular unit (del Zoppo, 2006) might be achieved through enhancing 
reperfusion, modifying neuronal activity, and augmenting neurorepair. Of these, 
reperfusion is effective with alteplase (Wardlaw et al., 2002) whilst neuroprotection 
has not been shown to be effective to date (Bath et al., 2001; Lees and Muir, 2002; 
Shuaib et al., 2007). One neuroprotectant showing promise is recombinant 
granulocyte colony stimulating factor (G-CSF). Its pharmacological and side effect 
profile is well known since G-CSF is already licensed for use in other indications in 
humans. 
 
G-CSF is a 207 amino acid glycoprotein cloned more than 20 years ago (Nagata et 
al., 1986). Its recombinant form is usually administered to patients with 
neutropenia to reduce the risk of sepsis, or to volunteers willing to donate 
haematopoietic stem cells (mobilised by G-CSF) for allogenic or autologous 
infusion. Endogenous G-CSF is produced by numerous cell types including 
monocytes (Vellenga et al., 1988) (the most abundant source), fibroblasts (Zucali 
et al., 1986), mesothelial and endothelial cells (Zsebo et al., 1988). G-CSF and its 
receptor are expressed in the penumbral region of ischaemic stroke (Schneider et 
al., 2005) and recent studies have highlighted its neuroprotectant properties as a 
possible therapy for cerebrovascular disease. G-CSF also stimulates the release of 
stem cells from the bone marrow and it could, therefore, also promote neurorepair 
(Sprigg and Bath, 2007). 
 
In light of ongoing human clinical trials assessing G-CSF in stroke, the purpose of 
this systematic review was to review systematically the effects of G-CSF in 
experimental stroke and, in particular, its effect on infarct size, motor impairment 
and death. 
MATERIALS AND METHODS 
 
Experimental (non-human) studies assessing the effects of G-CSF in ischaemic 
models of stroke (any species, age, sex and model) were sought with searches of 
Medline, Pubmed and Embase; search keywords included: ‘stroke’, 
‘cerebrovascular’, ‘thrombosis’, ‘brain’, ‘cerebral’, ‘cerebellum’, ‘middle cerebral 
artery’, ‘ischaemia’, ‘embolism’ and ‘G-CSF’. Searches were limited to animal 
studies. The reference lists of included articles and review articles were searched, 
and abstracts used to select relevant articles. Pre-specified exclusion criteria were 
used to aid selection and prevent bias and studies were included if the following 
were met: (i) a focal ischaemic stroke model, not global; (ii) treatment was in the 
acute/subacute phase i.e. <7 days, not chronic; (iii) no other potential 
neuroprotectants administered with G-CSF (i.e. confounded); (iii) measures on 
infarct size or functional outcome were performed; (iv) there was a control group; 
and (v) data was from an original article, not a letter or review article. Decisions on 
study inclusion and exclusion were made by TE and PB. 
 
Data Extraction 
Summary data on total infarct size, measured as volume or area (mm3, percentage 
of normal brain, or mm2) were extracted from all eligible papers up to June 2009. If 
given, infarct volume from total brain, cortex and subcortex were obtained 
separately. Volumes corrected for oedema were chosen in preference to 
uncorrected data. Similarly, information on vital status, weight (grams), Rotarod 
test (time spent on Rotarod expressed in seconds or percentage compared to 
baseline), motor impairment (low scores indicate a better outcome), foot fault 
(number of errors and percentage of total errors made), limb placement test 
(neurological scores) and locomotion (vertical movement and rearing) were also 
collected. If published studies used multiple groups (e.g. to assess dose-response 
relationships) then the number of animals in the control group was divided by the 
number of comparison groups. When numerical values were not available and 
contacted authors were unable to provide necessary information, published graphs 
were enlarged from the publication and the size of axes and position of data points 
estimated using Grab (version 1.3.1) on an Apple Mac. Methodological quality was 
assessed using methods previously described (Gibson et al., 2006; Willmot et al., 
2005) based on an 8-point STAIR criteria (STAIR 2009) with one point given for 
evidence of each of the following: presence of randomisation, monitoring of 
temperature (not just maintenance), assessment of effect by G-CSF dose, 
assessment of effect by time between stroke onset and treatment, masked 
outcome measurement, assessment of outcome at days 1–3, assessment of 
outcome at days 7–30, and assessment of outcome other than just lesion size. Two 
authors (TE and CG) independently assessed methodological quality and data 
extraction. 
 
Analysis 
Data were grouped before analysis by: (i) model type (permanent or transient 
ischaemia); (ii) species; (iii) time to treatment with G-CSF; and (iv) total dose of 
G-CSF. Data from each of these groups were analysed as forest plots using the 
Cochrane Review Manager software (version 4.2.10), as used in previous animal 
meta-analyses (Gibson et al., 2006; Willmot et al., 2005). Since heterogeneity was 
expected between study protocols (different species, stroke models, dose, time), 
random effect models were used. The results of continuous/ordinal data are 
expressed as Standardised Mean Difference (SMD), with 95% confidence intervals 
(CI), which allows data measured on different scales and in different species to be 
merged. The results of binary data are expressed as odds ratios (OR) with 95% CI. 
Studies were weighted by sample size and statistical significance was set at 
p<0.05. Publication bias was assessed by visually examining Begg’s funnel plot 
(standard error of SMD against the SMD); asymmetry in the plot was formally 
assessed using Egger’s test (Egger et al., 1997). 
RESULTS 
 
Design of Studies 
The initial search for studies identified 220 relevant publications (figure 1). Once 
pre-specified exclusion criteria were applied, a total of 19 publications were chosen 
for analysis (table 1); these came from 12 laboratories in 8 countries (China, 
France, Germany, Japan, South Korea, Taiwan, UK and USA). Only one negative 
study was identified in which G-CSF had a detrimental effect on behavioural 
function, caused brain atrophy and exaggerated the inflammatory response in the 
infarcted area (Taguchi et al., 2007). Studies excluded (table 2) were those 
administering G-CSF in combination with other agents such as stem cell factor 
(SCF) and those assessing chronic (i.e. >7 days post stroke) and global (transient 
bilateral common carotid artery occlusion) ischaemia. Of note, no functional 
improvement was seen with G-CSF in the studies of chronic (Zhao et al., 2007a) 
and global (Matchett et al., 2007) ischaemia; studies co-administering SCF reduced 
infarct volume in female mice (permanent ischaemia) by 50% (Toth et al., 2008) 
and improved functional recovery in acute and subacute phases (Kawada et al., 
2006). 
 
Of the 19 included publications, 14 studied rats, and 5 studied mice; hypertensive 
(1 of 18) and diabetic (1 of 18) rats were investigated but no studies in primates 
were identified. Some publications included more than one experimental condition, 
giving 44 studies in total (table 1). Studies included transient models of ischaemia 
(n=29) with vessel occlusion time ranging between 45 and 180 minutes. Permanent 
models were used in 12 studies; and a photothrombotic model, which is less likely 
to negatively affect survival, was used in 3 studies, each of which only assessed 
functional outcome. All photothrombotic models used direct illumination of the 
cortex after sensitisation with the dye rose bengal to produce a focal infarct. G-CSF 
was given via various routes (subcutaneously n=30, intravenously n=12, and intra-
peritoneum n=4) and at various dose regimens (total dose range 50 to 3000 
mcg/kg) and time from onset of ischaemia (range from -96 hours to 1 week with 
68% of animals having ischaemia for <2 hours). Infarct size was measured either 
histologically (staining with triphenyltetrazolium chloride [TTC], toluidine blue, 
haematoxylin and eosin, or cresyl violet) or with MRI evaluation (T2 weighted 
images). 
 
Infarct Size 
26 studies from 19 publications (table 1) assessed the effects of GCSF on lesion 
size in a total of 412 animals (318 rats, 94 mice). All studies measuring infarct 
volume had protocols which required that G-CSF be administered within 24 hours. 
22 of 26 studies measured these effects following transient ischaemia (table 3, 
figure 2). The presence of publication bias is suggested by a positive Egger’s test of 
asymmetry (p<0.001, figure 3). Overall, G-CSF significantly reduced lesion size in 
transient ischaemia (SMD -1.63, 95% CI -2.14 to -1.11, p<0.00001). In the 4 
studies using a permanent model (56 animals), G-CSF did not significantly reduce 
lesion size (SMD -1.53, 95% CI -3.42 to 0.36, p=0.11). Significant reductions in 
lesion size were seen in both rats and mice in transient (figure 2) but not 
permanent ischaemia. When only including the 21 studies that reported lesion 
volume (in mm3) in transient ischaemia, the weighted mean difference was -62.32 
(95% CI -79.6 to -45.1); equivalent to a SMD of -1.59 (95% CI -2.12 to -1.06). 
 
Motor Impairment 
G-CSF significantly reduced neurological deficit (SMD -1.37, 95% CI -2.13 to -0.61, 
p=0.0004) in 11 studies (Komine-Kobayashi et al., 2006; Sehara et al., 2007a; 
Sevimli et al., 2009; Solaroglu et al., 2009; Taguchi et al., 2007; Yanqing et al., 
2006). Impairment was measured at various time points post stroke (1, 2, 3, 7, 14, 
21 and 35 days); beneficial effects of G-CSF were seen at all times but there was 
no correlation between reduction in impairment and time to measurement (rs= 
0.37, p=0.47). G-CSF increased time that animals stayed on a Rotarod (Gibson et 
al., 2005a; Lee et al., 2005; Schneider et al., 2006; Sevimli et al., 2009) (table 3) 
at 1 and 5 weeks post ischaemia. Similarly, improvements were seen in limb 
function as assessed by limb placement tests at 1 and 4 weeks post stroke. This 
was not reflected, however, in locomotor activity (at 4 and 5 weeks), as assessed 
by vertical movements / rearing, where there was no difference between G-CSF 
and control (SMD 0.76, 95% CI -0.98 to 2.51, p=0.35) (Shyu et al., 2004b; 
Taguchi et al., 2007). 
 
Survival 
Data on vital status was available in 6 studies (Gibson et al., 2005a; Schabitz et al., 
2003; Schneider et al., 2005; Sevimli et al., 2009; Six et al., 2003; Yanqing et al., 
2006); G-CSF reduced the odds of dying almost 4-fold (OR 0.27, 95% CI 0.14 to 
0.51, p<0.0001). 
 
Total G-CSF dose 
G-CSF administration varied considerably between studies: in studies using higher 
doses, regimens divided the G-CSF dose over a number of days (table 1). In an 
indirect comparison assessing total administered dose in transient ischaemia, a 
significant reduction in lesion size occurred at all doses (dose range 50 to 3000 
mcg/kg) (figure 4). None of the doses used in permanent ischaemia (50 to 350 
mcg/kg) had a significant effect on infarct size. No studies compared lesion size 
with 2 or more doses of G-CSF but one study displayed impaired behavioural 
function with increasing doses of G-CSF (0.5 to 250 mcg/kg) (Taguchi et al., 2007). 
 
Timing of treatment 
G-CSF was administered pre-ischaemia in one study (Sevimli et al., 2009) and only 
one study compared time to treatment (Lee et al., 2005). Significant reductions in 
lesion size in transient models of ischaemia were seen with treatment started within 
4 hours post-ischaemia; trends to efficacy were also seen with commencement at 5 
and 24 hours post-onset of ischaemia (data not shown).  
 
Study Quality 
The median study quality score was 4 (out of 8) with range 0 to 7. The majority of 
included studies were randomised (Gibson et al., 2005a; Gibson et al., 2005b; Han 
et al., 2008; Komine-Kobayashi et al., 2006; Lan et al., 2008; Lee et al., 2005; 
Schabitz et al., 2003; Schneider et al., 2005; Schneider et al., 2006; Sehara et al., 
2007a; Sehara et al., 2007c; Sevimli et al., 2009; Solaroglu et al., 2006; Solaroglu 
et al., 2009; Yanqing et al., 2006; Zhao et al., 2007c) and used blinded outcome 
assessments (Gibson et al., 2005a; Gibson et al., 2005b; Komine-Kobayashi et al., 
2006; Lan et al., 2008; Lee et al., 2005; Schabitz et al., 2003; Schneider et al., 
2005; Schneider et al., 2006; Sehara et al., 2007a; Sevimli et al., 2009; Shyu et 
al., 2004a; Solaroglu et al., 2006; Solaroglu et al., 2009; Taguchi et al., 2007; 
Yanqing et al., 2006; Zhao et al., 2007c) and although each study varied in G-CSF 
dose regimen, only one study specifically addressed the optimal time window of 
drug administration (Lee et al., 2005). One study assessed dose response (Taguchi 
et al. 2007). After adjusting for the number of animals in each study, the effect of 
G-CSF on lesion size was not related with study quality (Spearman’s rank 
correlation, rs=-0.16, p=0.7). 
DISCUSSION 
 
This systematic review finds that G-CSF reduces lesion size in transient ischaemia 
within 4 hours of administration, motor impairment (neurological severity and limb 
function) and death in experimental stroke. No significant effects were seen in 
permanent ischaemic models or in long term locomotor activity. Of note, the 
identified studies were biased towards those which might be expected to be 
positive, i.e. most studies assessed transient (32 experiments) rather than 
permanent (12 experiments) ischaemia, and short rather than long ischaemia. 
 
The mechanisms of action of these potential effects are under investigation and are 
probably multi-factorial. First, neuroprotective activity may be secondary to 
suppression of oedema formation (Gibson et al., 2005b), reduction of inflammation 
(Gibson et al., 2005b; Lee et al., 2005; Sehara et al., 2007a) (although G-CSF has 
also been reported to exacerbate the inflammatory response within the peri-infarct 
area (Taguchi et al., 2007)), and anti-apoptotic effects (with reduced cell death in 
the ischaemic penumbra) (Komine-Kobayashi et al., 2006; Schneider et al., 2005; 
Solaroglu et al., 2006). Second, CD34+ haematopoietic stem cells (which are 
mobilised by G-CSF) are able to migrate to the site of injury when administered 
either intracerebrally or intravenously (Jendelova et al., 2005; Sykova and 
Jendelova, 2005). Transplanted human bone marrow cells have been shown to 
generate neurons and astrocytes (Crain et al., 2005) but the ability of migratory 
stem cells to help restore functional and structural recovery post stroke has been 
questioned; in one study, bone marrow derived cells spontaneously fused, in vivo, 
with recipient Purkinje neurons in the cerebllum with no evidence of 
transdifferentiation (Alvarez-Dolado et al., 2003). Neurogenesis (Schneider et al., 
2005; Sehara et al., 2007c; Shyu et al., 2004a) needs to be sufficient and 
angiogenesis (Lee et al., 2005; Sehara et al., 2007c; Shyu et al., 2004a) is also 
necessary. In rats, G-CSF is able to cross the blood brain barrier when administered 
exogenously (Schneider et al., 2005)  and both G-CSF and its receptor are widely 
expressed from neurons in the in the CNS (Schneider et al., 2005). In addition, a 
recent post mortem series highlighted G-CSF receptor upregulation in human 
ischaemic stroke (Hasselblatt et al., 2007). Though these findings are encouraging, 
species differences in the expression profile of G-CSF should be considered which 
could alter the effect it has on infarct volume reduction and functional recovery.  
 
The optimal time of administration of G-CSF relative to stroke onset (0-4 hours) 
supports a role of neuroprotective mechanisms but whether neuroreparative actions 
occur is far less clear since only trends to efficacy were seen between 5 and 24 
hours. However, these data were limited and neurorepair may need stimulation 
after 24 hours when inflammatory responses have declined (England et al., 2009). 
Nevertheless, further studies are required to determine the extent of the 
therapeutic window. Moreover, the most appropriate G-CSF dose and 
administration regimen still needs to be established. A positive correlation was seen 
between total G-CSF dose and lesion size reduction but the true dose-response 
relationship requires confirmation in a study designed to answer this. 
 
Furthermore, the infarct type (transient or permanent ischaemia) requires 
consideration. Our analysis confirms efficacy of G-CSF in rodents with transient 
ischaemia within 4 hours of administration but a closer analogy to treating a large 
proportion of human stroke would be a permanent ischaemic model treated beyond 
4 hours – a combination without evidence in this review. However, the data are 
limited and the smaller number of animals tested in the permanent ischaemic 
model may account for the lack of significance. Human stroke is also increasingly 
treated with thrombolytic agents and no articles were identified (except for one 
abstract (Kollmar et al., 2007)) assessing G-CSF in combination with tissue 
plasminogen activator (t-PA). This is especially important for potential 
neuroprotective agents which have to be administered early. Other stroke models 
could also influence lesion volume and recovery, for example, the presence of co-
morbidities such as diabetes, hypertension, hypercholesterolaemia, female species 
and increasing age. Ideally all should be tested for their confounding effects (Fisher 
et al., 2009). 
 
However, the potential beneficial effects observed here could be artifactual in view 
of the presence of potential publication bias, detected for the effect of G-CSF on 
lesion size caused by transient ischaemic models. This suggests that neutral or 
negative studies were not published, or at least not identified despite using a 
comprehensive search strategy. It is possible that these studies have been 
published in a journal not included in MEDLINE or EMBASE, or that investigators 
deliberately did not publish neutral/negative data, or that such studies are not 
attractive to journal reviewers and Editors. 
 
We assessed study quality on the basis of methodological recommendations derived 
from the STAIR consortium (STAIR, 1999) and found no relationship between study 
quality and effect on lesion size. STAIR standards were developed by an expert 
panel to address why so many clinical trials of neuroprotectants have failed, and we 
have previously used this scale in other meta-analyses of experimental regimes for 
stroke (Gibson et al., 2006; Willmot et al., 2005). Although the majority of studies 
in this review had written evidence of randomisation (16/19 publications) and 
blinded outcome assessment (16/19), important sources of bias if unused (Crossley 
et al., 2008; Macleod et al., 2009), other key methodological  criteria were missing, 
including assessment of dose-response (1/19) and time-response (2 of 19). It is, of 
course, possible that these criteria were not reported rather than not being 
performed. Furthermore, the majority of studies reporting randomisation and 
blinded outcome assessment was significantly higher than in other stroke reviews 
(Sena et al., 2007) and may explain why no study quality effect was observed here. 
 
Meta-analysis methodology has a number of limitations and several caveats need to 
be identified for this systematic review. First, its findings depend on the success of 
identifying all relevant studies; the non-inclusion of some studies, perhaps due to 
non-publication (‘publication bias’) means that the estimated treatment effects may 
be an over- or an under-estimate. Second, the results depend on study quality (so 
assignment and observer bias are minimised). Third, study design determines what 
data are available for each included study; e.g. Rotarod and limb placement 
assessments largely came from one study (Lee et al., 2005) thereby restricting 
interpretation. Fourth, differences in methodology and study quality limit 
interpretation and introduce heterogeneity in findings, a problem that is addressed, 
in part, by using random effects models; e.g. analysing using standardised mean 
differences allows for comparison of infarct size whether measured by volume, area 
or percentage. Last, the selection process of suitable publications has the potential 
to introduce its own bias. 
 
Of note, an earlier systematic review was published whilst the current one was 
being analysed. This former review observed a 0.8% reduction in infarct volume 
per 1 g/kg increase in G-CSF dose (Minnerup et al., 2008). However, it included 
fewer articles (13 publications), excluded studies appropriate for analysis (Hermann 
and Kilic, 2008; Sehara et al., 2007c; Taguchi et al., 2007) and found no evidence 
of publication bias.  
 
In summary, G-CSF appears to have neuroprotective qualities, although the results 
are limited in nature and potentially biased. Nonetheless, G-CSF offers a potential 
multimodal therapy for ischaemic stroke and it is possible that meaningful 
reductions in infarct volume and improvements in functional recovery are translated 
into human trials. However, further experimental studies are required, in particular, 
assessing permanent models of ischaemia, length of ischaemia, other species (such 
as primates), both sexes, and animals with other co-morbidities and of increasing 
age (i.e. mimicking patients with stroke) (Fisher et al., 2009). Studies also need to 
address optimal dose and route regimens, and elucidation of time responses. 
Acquiring this information is key since clinical trials assessing the safety of G-CSF in 
human stroke are already underway (Bath and Sprigg, 2006; Shyu et al., 2006; 
Sprigg et al., 2006). 
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Figure 1 
Summary of trial identification process 
 
Figure 2.  
Effect of G-CSF on lesion volume in transient middle cerebral artery occlusion (N, 
number of animals; SMD, standardised mean difference; 95% CI, 95% confidence 
interval; SD, standard deviation; MCAo, middle cerebral artery occlusion) 
 
Figure 3.  
Begg’s funnel plot showing the relationship between lesion volume (standardised 
mean difference, SMD) and standard error of SMD. Smaller neutral or negative 
studies (i.e. where lesion volume was not altered by G-CSF or increased with it) are 
missing suggesting the presence of publication bias (Egger’s test p<0.001). 
 
Figure 4.  
Effect of total G-CSF dose (logged) on lesion volume in models of transient 
ischaemia. Data expressed as standardised mean difference (SMD) and 95% 
confidence intervals. Significant reductions in lesion volume: * p<0.05; ** 
p<0.001, # p<0.0001, ## p<0.00001 
Table 1. Included Studies 
Study Parameters assessed [time of assessment] GCSF dose 
(µg/kg) 
Time to 
Treatment 
(hours) 
Species Model Route STAIR 
score 
Gibson 2005a 
Experiment 1 
Infarct volume (mm3) [48 hours] 
50 1 
Adult male CL57 
BL/6 mice  
T 60mins s.c. 6 
Experiment 2 
Rotarod, foot fault [daily for 7 days],  
Morris water maze [days 15 to 20] 
Gibson 2005b Infarct volume (mm3) [48 hours], survival 50 0 
Adult male CL57 
BL/6 mice  
P s.c. 4 
Han 2008  
Experiments 1-3 
Infarct volume (mm3) [4, 16 and 24 hours] 60 0.5 Male Wistar rats T 60mins i.v. 3 
Kobayashi 2006  
Experiments 1-2 
Infarct volume (mm3), neurological deficit (0-3 
scale) [24 and 72 hours] 
50 0.5 
Adult male CL57 
BL/6 mice 
T 60mins i.v. 4 
Lan 2008  
Experiment 1-3 
Infarct volume (mm3), NSS (0-18 scale) [days 7, 14 
and 21] 
50 for 7, 14 
and 21 days 
0 
Male Sprague 
Dawley diabetic 
rats 
P s.c. 4 
Lee 2005  
Experiment 1 
Infarct volume (mm3) [day 1] 
50 for 3 days 
2 
Male Sprague 
Dawley rats 
T 90mins i.p. 7 
Experiments 2-4 
 
Rotarod (% of baseline), MLPT (0-7 scale) [1 week 
before and weekly  for 5 weeks post ischaemia] 
2, 24, 96 
and 168 
Schneider 2005  
Experiment 1 Infarct volume (mm3), survival  60 2 
Male Wistar rats 
T 90mins 
i.v. 5 Experiment 2 
Infarct volume (mm3), Rotarod (seconds and AUC), 
NSS* (0-16 scale) [72 hours] 
50 1 T 180mins 
Experiment 3 
Rotarod (seconds and AUC), NSS* (0-16 scale) 
[weekly, 2 to 6 weeks post ischaemia] 
15 for 5 days 1 
Photo-
thrombotic 
Schneider 2006  
Experiment 1 Infarct volume (mm3) [24 hours] 
60 4 
Male Wistar rats 
T 90mins 
i.v. 6 
Experiments 2-3 
Rotarod (seconds and AUC) [weekly, 1 to 6 weeks 
post ischaemia] 
10 for 10 days 24 and 72 
Photo-
thrombotic 
Schabitz 2003  Infarct volume (mm3) [24 hours], survival 60 0.5 Male Wistar rats T 90mins i.v. 4 
Sehara 2007a  
Experiment 1 
Infarct volume (mm3) [72 hours] 
50 1.5 
Adult male 
Wistar rats 
T 90mins s.c. 4 
Experiment 2 Neurological deficit (0-3 scale) [24 and 72 hours] 
Sehara 2007b  Infarct area (mm2) [day 7] 
 
50 
1.5 
Adult male 
Wistar rats 
T 90mins s.c. 2 
Solaroglu 2009 
Experiment 1 
Infarct volume (mm3) [24 hours] 
50 1.5 
Adult male 
Sprague Dawley 
rats 
T 90 mins s.c. 5 
Experiment 2 Neurological score (scale 3-18) [24 hours] 
Taguchi 2007 
Experiment 1  Infarct area (mm2) [72 hours] 
50 for 3 days 
24 CB-17 mice P s.c. 6 
Experiments 2-3 
 Locomotor activiity (rearing) and neurological 
deficit [35 days] 
0.5, 5, 50 or 
250 for 3 days 
Yanqing 2006  
Experiments 1-3 
Infarct volume (mm3), survival, NSS (0-18 scale) 
[7, 14 and 21 days] 
10 for 5 days 5 
Male Sprague 
Dawley rats 
T 60mins s.c. 4 
Zhao 2007b 
Experiment 1 Infarct volume (%) [12 weeks] 
50 for 7 days 3 
Male 
hypertensive 
rats 
P s.c. 4 
Experiments 2-3  
Foot fault, limb placement test [1, 4, 7 and 10 
weeks] 
T, transient ischaemia; P, permanent ischaemia; s.c., subcutaneous; i.v., intravenous; i.p., intraperitoneal; NSS, neurological severity score; AUC, area under the curve; 
MLPT, modified limb placement test 
 
Sevimli 2009 
Experiment 1 
Infarct volume (mm3) [48 hours] 
250 bd for 6 
days 
-96 
G-CSF deficient 
female C57BL/6 
mice 
T 45mins s.c. 5 
Experiment 2 Neurological deficit (0-5 scale) [24 and 48 hours] 
Experiment 3 Rotarod (seconds), survival 
Shyu 2004 
Experiment 1  Infarct volume (mm3) [day 7], 
50 for 5 days 24 
Adult Sprague 
Dawley male 
rats 
T 90mins s.c. 4 
Experiment 2 
Body swing test (% recovery) and locomotor activity  
(vertical movement)  [days 1 to 28] 
Six 2002  Infarct volume (mm3) [4 days], survival 50 24 
Male CL57 BL/6 
Mice 
T 60mins s.c. 0 
Solaroglu 2006  
Experiment 1 Infarct volume (mm3) [24 hours] 
50 
1.5 
Adult male 
Sprague Dawley 
rats 
T 90mins s.c. 5 
Experiment 2 Infarct volume (mm3) [72 hours]  50 for 2 days 
Experiment 3 Neurological deficit [24, 48 and 72 hours] 50 for 2 days 
Table 2. Excluded studies 
Study Reason for exclusion and comments.  
(Toth et al., 2008) G-CSF given in combination with SCF in a permanent MCAo mouse model. Treatment induced infarct 
volume reduction and enhanced angiogenesis. 
(Morita et al., 2007) Assessed inflammatory marker expression in mice with permanent ischaemia treated with a combination of 
G-CSF and SCF in acute (1 to 10 days) and subacute (11 to 20 days) phases. No assessment on functional 
recovery or infarct volume 
(Zhao et al., 2007a) Treatment given to rats with chronic ischaemia (3.5 months post stroke). No benefit seen in functional 
outcome in rats given G-CSF alone. SCF alone and in combination with G-CSF improved functional outcome. 
(Yata et al., 2007) 
(Kim et al., 2008) 
Rat models of neonatal hypoxia. No assessments of infarct volume or functional recovery. Treatment with 
G-CSF improved quantitative brain weight (Yata et al., 2007) and inhibited apoptosis (Kim et al., 2008). 
(Kawada et al., 2006) G-CSF given in combination with SCF acutely and subacutely. Permanent MCAo model used. Reduction in 
infarct volume and enhanced functional recovery. 
(Matchett et al., 2007) Effect of G-CSF on global cerebral ischaemia. No long-term (2 weeks) protection seen in neurobehavioural 
studies. 
(Zhao et al., 2007b) Observed that G-CSF and SCF pass through an intact blood-brain barrier in intact rats. No stroke induced. 
(Chen et al., 2005) Article in Chinese and unable to acquire to translate. 
(Willing et al., 2003) Transplanted peripheral blood progenitor cells (mobilised by G-CSF) and human umbilical cord-blood 
derived stem cells in rats 24 hours after permanent MCAo. Compared to control, a reduced stroke-induced 
hyperactivity was observed in the transplanted animals. 
(Hokari et al., 2009) Bone marrow stromal cells (BMSC), pre-treated with G-CSF, transplanted into mouse stroke brain, 
enhanced motor function earlier than mice treated with ‘non-treated’ BMSC. 
(Muller et al., 2009)  Compared neurotransmitter profile in rats subjected to photothrombotic ischaemia treated with either G-
CSF or brain derived neurotrophic factor (BDNF). No infarct volumes or functional outcome measures. 
(Sehara et al., 2007b) In a rat model of transient MCAo, G-CSF enhanced cell proliferation in the dentate gyrus. No measures of 
infarct volume or functional outcome.  
SCF Stem Cell Factor; MCAo middle cerebral artery occlusion 
Table 3. Effect of G-CSF on lesion volume, functional outcome and survival  
(SMD, standardised mean difference; OR, odds ratio; 95% CI, 95% confidence interval; IS, ischaemic stroke) 
 
 No of Studies No of Animals SMD 95% CI p-value 
Lesion Volume 
Transient IS 22 356 -1.63 (-2.14, -1.11) < 0.00001 
Permanent IS 4 56 -1.53 (-3.42, 0.36) 0.11 
Mice 7 94 -1.61 (-2.81, -0.40) 0.009 
Rats 19 318 -1.58 (-2.12, -1.04) < 0.00001 
Motor Impairment 
Neurological deficit 11 108 -1.37 (-2.13, -0.61)  0.0004 
Rotarod (<1 week post IS) 5 87 1.11 (0.16, 2.06) 0.02 
Rotarod (5 weeks post IS) 6 115 3.24 (1.63, 4.85) < 0.0001 
Foot fault (1 week post IS) 2 32 -0.45 (-2.10, 1.19) 0.59 
Limb placement (1 week post IS) 5 95 -0.97 (-1.91, -0.04) 0.04 
Limb placement (4 weeks post IS) 5 95 -2.17 (-3.61, -0.72) 0.003 
Locomotor activity (>4 weeks post 
IS) 
5 54 1.75 (-1.89, 5.38) 0.35 
 No of Studies No of Animals OR 95% CI p-value 
Survival 
Transient ischaemia 6 230 0.27 (0.14, 0.451) < 0.0001 
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Figure 2.  
Effect of G-CSF on lesion volume in transient middle cerebral artery occlusion (N, number of animals; SMD, standardised 
mean difference; 95% CI, 95% confidence interval; SD, standard deviation; MCAo, middle cerebral artery occlusion) 
 
 
Figure 3.  
Begg’s funnel plot showing the relationship between lesion volume (standardised mean difference, SMD) and standard error 
of SMD. Smaller neutral or negative studies (i.e. where lesion volume was not altered by G-CSF or increased with it) are 
missing suggesting the presence of publication bias (Egger’s test p<0.001). 
 
 
 
Figure 4.  
Effect of total G-CSF dose (logged) on lesion volume in models of transient ischaemia. Data expressed as standardised mean 
difference (SMD) and 95% confidence intervals. Significant reductions in lesion volume: * p<0.05; ** p<0.001, # p<0.0001, 
## p<0.00001 
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